燃石医学 Burning Rock Biotech

A groundbreaking study published in Cell Reports Medicine highlights a new hope for EGFR-mutant NSCLC patients. The study provides supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC. Notably, ctDNA was used as a biomarker to dynamically monitor minimal residual disease, aiding in the identification of patients responding to the treatment. This study, supported by Burning Rock's personalized MRD product, brPROPHET, underscores the importance of preoperative MRD testing in guiding dynamic monitoring and study design for patients with tumor gene mutations. 🔗 Read more: https://lnkd.in/gUDxmraw #LungCancer #CellReportsMedicine #BurningRock

Today, we celebrate the powerful bond between sports, wellness, and healthcare. At Burning Rock Dx, we are dedicated to advancing human health and recognize the pivotal role of physical activity in promoting overall well-being. 🏅🌍 International Olympic Day is a reminder of the positive impact that athletic endeavors have on individual health and community resilience. It highlights values like determination, teamwork, and perseverance—values that align with our mission to enhance lives through innovative diagnostics and personalized healthcare solutions. On this special day, let's embrace the Olympic spirit to promote healthy living and emphasize the importance of integrating sports into healthcare. Together, we can champion a healthier and more active world. Happy International Olympic Day from all of us at Burning Rock Dx! #OlympicDay

Burning Rock Dx Spotlight: OncoCompass® Target   Introducing a Reliable and Evidence-based ctDNA Testing Solution   We are proud to introduce OncoCompass® Target, a CE-certified liquid biopsy tool that sets the standard in ctDNA testing. Backed by rigorous performance validations and extensive research, OncoCompass® Target delivers exceptional accuracy and specificity, ensuring reliable results for targeted therapy and cancer management.   Key Highlights: · Comprehensive Validation: Proven high sensitivity, specificity, and reproducibility. · Extensive Research: Over 90 papers published since 2020. · Clinical Utility: Supports targeted therapy, immuno-oncology, and germline specific gene analysis. Stay tuned as we dive deeper into some of the groundbreaking research supporting OncoCompass® Target. For more information, feel free to reach out to us at PBD@brbiotech.com.   #LiquidBiopsy #ctDNA #BurningRockDx

Our colleague Chun (Michael) Chen , PharmD, is presenting today at the Immuno-Oncology hubXchange conference in Boston! 🎤✨ His keynote topic is: "Exploring the potential: harnessing ctDNA MRD in immune-oncology treatment for solid tumors." Our team members will be at the conference all day, eager to engage with all attendees. Looking forward to discussing the latest advancements in immuno-oncology! If you're at the event, be sure to connect with us! #ImmunoOncology #BurningRockDx #ctDNA #MRD

Happy Father's Day.

We are excited to share that Chun (Michael) Chen, PharmD, from Burning Rock Dx, will be presenting at the Immuno-Oncology Xchange run by hubXchange Join us for his keynote presentation titled: "Exploring the potential: harnessing ctDNA MRD in immune-oncology treatment for solid tumors." 🗓 Date: June 18, 2024 🕒 Time: 8:30 - 9:00 AM 📍 Woburn Hilton Hotel, Boston MA 01801 In addition, our talented team members ，Shawn A. , Alex Brand and Liliang Jin will also be attending the conference. This is a fantastic opportunity to connect and discuss the latest advancements in immuno-oncology. #ImmunoOncology #CancerResearch #BurningRockDx #ctDNA #MRD

燃石医学祝大家端午安康！ 一城粽叶炊烟袅袅竞飘香， 满堂艾蒲祈愿岁岁常安康。

Burning Rock Dx Spotlight: brPROPHET We're excited to highlight the latest advancements in our MRD detection product, brPROPHET, showcased at the recent ASCO conference! Since its market launch on March 1, 2022, brPROPHET has been empowering precision clinical research. Here's what we've achieved so far: 1. Featured in 12 posters at AACR, ASCO, and ESMO 2. Published a paper in Cancer Cell Discover more about brPROPHET and its groundbreaking impact on MRD detection. For detailed information, check the attachment or contact us at PBD@brbiotech.com. Stay tuned for more exciting results coming soon! #MRD #PrecisionMedicine #BurningRockDx

🌍 World Environment Day: Our Commitment to Sustainability On this World Environment Day, Burning Rock Dx reaffirms our dedication to environmental sustainability. Our mission is to drive advancements in medical technology while championing sustainable practices. 🚀 Our Key Initiatives: 1. Greenhouse Gas Inventory: Verified under ISO 14064-3:2019. 2. Global Platforms: Active on EcoVadis and CDP (Carbon Disclosure Project). 3. Science-Based Targets Initiative（SBTi）: Committed to the SBTi, with emission reduction targets under review. We are committed to transparency, social value, and responsibility for our planet's future. Together, let's build a sustainable world through innovation and responsible practices. #WorldEnvironmentDay #Sustainability #BurningRockDx

What an incredible experience at ASCO 2024! Our team had a fantastic experience showcasing our innovations with 11 posters. It was a pleasure connecting with global attendees. Already counting down the days until next year's meeting! #ASCO24 #BurningRock